Key facts
- This page summarizes Michael Vangsted Jensen's Form 4 filing for SYNLOGIC, INC. (SYBX).
- 6 reported transactions and 6 derivative rows are listed below.
- Accepted by SEC: 14 Nov 2023, 19:22.
Michael Vangsted Jensen - 10 Nov 2023 Form 4 Insider Report for SYNLOGIC, INC. (SYBX)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- SYBX
- Reported as of
- 10 Nov 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Nov 2023, 19:22:53 UTC
- Prior SEC filing
- 05 Apr 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Vangsted Jensen
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Michael Vangsted Jensen filed Form 4 for SYNLOGIC, INC. (SYBX) on 14 Nov 2023.
Change
- Previous filing in this sequence was filed on 05 Apr 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SYBX
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -15,332
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 10 Nov 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,332
- Exercise price
- $33.45
- Footnotes
- F1, F2
SYBX
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -13,332
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 10 Nov 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 13,332
- Exercise price
- $9.30
- Footnotes
- F1, F3
SYBX
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -6,666
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 10 Nov 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,666
- Exercise price
- $9.30
- Footnotes
- F1, F4
SYBX
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- Shares
- +15,332
- Change %
- Price
- Shares after
- 15,332
- Date
- 10 Nov 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,332
- Exercise price
- $1.85
- Footnotes
- F1, F2
SYBX
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- Shares
- +13,332
- Change %
- Price
- Shares after
- 13,332
- Date
- 10 Nov 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 13,332
- Exercise price
- $1.85
- Footnotes
- F1, F3
SYBX
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- Shares
- +6,666
- Change %
- Price
- Shares after
- 6,666
- Date
- 10 Nov 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,666
- Exercise price
- $1.85
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements.
Footnote F2
These stock options vested 25% on the first anniversary of the March 3, 2022 grant date, and vest in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.
Footnote F3
The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2023 through April 1, 2027.
Footnote F4
These performance-based stock options, granted on March 16, 2023, vest when the achievement of certain clinical and regulatory development milestones are met.